Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation

Chemistry and Biology

Volumn 22, Issue 4, 2015, Pages 472-482

  Corbel, Caroline ^a,b   Zhang, Bing ^c   Le Parc, Annabelle ^b   Baratte, Blandine ^a   Colas, Pierre ^a   Couturier, Cyril ^d   Kosik, Kenneth S ^b   Landrieu, Isabelle ^b,d   Le Tilly, Véronique ^b   Bach, Stéphane ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b ENSTA BRETAGNE   (France)

^c NORTH CHINA ELECTRIC POWER UNIVERSITY   (China)

^d UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CDCA5 PROTEIN, HUMAN; CDK5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE 5; NERVE PROTEIN; P25 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAMOXIFEN; TAU PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL CULTURE; CHEMISTRY; CYTOLOGY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; METABOLISM; MOLECULAR DOCKING; NERVE CELL; PHOSPHORYLATION; PROTEIN DOMAIN; RAT; SPRAGUE DAWLEY RAT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BINDING SITES; CELL CYCLE PROTEINS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 5; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MOLECULAR DOCKING SIMULATION; NERVE TISSUE PROTEINS; NEURONS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TAU PROTEINS;

EID: 84937763225     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.03.009     Document Type: Article

References (53)

1. A.K. Ajay, A.K. Upadhyay, S. Singh, M.V. Vijayakumar, R. Kumari, V. Pandey, R. Boppana, and M.K. Bhat Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression Mol. Cancer 9 2010 204
2. J. Bacart, C. Corbel, R. Jockers, S. Bach, and C. Couturier The BRET technology and its application to screening assays Biotechnol. J. 3 2008 311 324
3. S. Bach, M. Knockaert, J. Reinhardt, O. Lozach, S. Schmitt, B. Baratte, M. Koken, S.P. Coburn, L. Tang, and T. Jiang Roscovitine targets, protein kinases and pyridoxal kinase J. Biol. Chem. 280 2005 31208 31219
4. H.J.C. Berendsen, J.P.M. Postma, W.F. van Gunsteren, A. Di-Nola, and J.R. Haak Molecular dynamics with coupling to an external bath J. Chem. Phys. 81 1984 3684 3690
5. S.B. Bharate, S.D. Sawant, P.P. Singh, and R.A. Vishwakarma Kinase inhibitors of marine origin Chem. Rev. 113 2013 6761 6815
6. B. Breuer, and R. Anderson The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents Women Health 31 2000 71 85
7. C. Cai, X. Chen, and F. Ge Analysis of interaction between tamoxifen and ctDNA in vitro by multi-spectroscopic methods Spectrochim. Acta A Mol. Biomol. Spectrosc. 76 2010 202 206
8. D.A. Case, T.A. Darden, T.E. Cheatham III, and C.L. Simmerling AMBER 9 2006 University of California San Francisco
9. H.M. Chow, D. Guo, J.C. Zhou, G.Y. Zhang, H.F. Li, K. Herrup, and J. Zhang CDK5 activator protein p25 preferentially binds and activates GSK3beta Proc. Natl. Acad. Sci. USA 111 2014 E4887 E4895
10. R.M. Cohen, K. Rezai-Zadeh, T.M. Weitz, A. Rentsendorj, D. Gate, I. Spivak, Y. Bholat, V. Vasilevko, C.G. Glabe, and J.J. Breunig A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss J. Neurosci. 33 2013 6245 6256
11. E. Contreras-Vallejos, E. Utreras, and C. Gonzalez-Billault Going out of the brain: non-nervous system physiological and pathological functions of Cdk5 Cell. Signal. 24 2012 44 52
12. C. Corbel, Q. Wang, H. Bousserouel, A. Hamdi, B. Zhang, O. Lozach, Y. Ferandin, V.B. Tan, F. Gueritte, and P. Colas First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors Biotechnol. J. 6 2011 860 870
13. W.D. Cornell, P. Cieplak, C.I. Bayly, I.R. Gould, K.M. Merz, D.M. Ferguson, D.C. Spellmeyer, T. Fox, J.W. Caldwell, and P.A. Kollman A second generation force field for the simulation of proteins,nucleic acids, and organic molecules J. Am. Chem. Soc. 117 1995 5179 5197
14. J.C. Cruz, and L.H. Tsai Cdk5 deregulation in the pathogenesis of Alzheimer's disease Trends Mol. Med. 10 2004 452 458
15. T. Darden, D. York, and L. Pedersen Particle mesh Ewald: an N.log(N) method for Ewald sums in large systems J. Chem. Phys. 98 1993 10089 10092
16. P. de Medina, G. Favre, and M. Poirot Multiple targeting by the antitumor drug tamoxifen: a structure-activity study Curr. Med. Chem. Anticancer Agents 4 2004 491 508
17. R. Dhavan, and L.H. Tsai A decade of CDK5 Nat. Rev. Mol. Cell Biol. 2 2001 749 759
18. H.H. Feldman, M. Haas, S. Gandy, D.D. Schoepp, A.J. Cross, R. Mayeux, R.A. Sperling, H. Fillit, D.L. van de Hoef, and S. Dougal Alzheimer's disease research and development: a call for a new research roadmap Ann. N Y Acad. Sci. 1313 2014 1 16
19. G. Feldmann, A. Mishra, S.M. Hong, S. Bisht, C.J. Strock, D.W. Ball, M. Goggins, A. Maitra, and B.D. Nelkin Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling Cancer Res. 70 2010 4460 4469
20. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, and J.K. Perry Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
21. S. Goodyear, and M.C. Sharma Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5 Exp. Mol. Pathol. 82 2007 25 32
22. D. Guiffant, D. Tribouillard, F. Gug, H. Galons, L. Meijer, M. Blondel, and S. Bach Identification of intracellular targets of small molecular weight chemical compounds using affinity chromatography Biotechnol. J. 2 2007 68 75
23. A. Hamdi, and P. Colas Yeast two-hybrid methods and their applications in drug discovery Trends Pharmacol. Sci. 33 2012 109 118
24. M.J. Harper, and A.L. Walpole A new derivative of triphenylethylene: effect on implantation and mode of action in rats J. Reprod. Fertil. Suppl. 13 1967 101 119
25. V.C. Jordan Tamoxifen: a most unlikely pioneering medicine Nat. Rev. Drug Discov. 2 2003 205 213
26. J.K. Laha, X. Zhang, L. Qiao, M. Liu, S. Chatterjee, S. Robinson, K.S. Kosik, and G.D. Cuny Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors Bioorg. Med. Chem. Lett. 21 2011 2098 2101
27. J.H. Lee, and K.T. Kim Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells J. Neurochem. 91 2004 634 647
28. M.S. Lee, Y.T. Kwon, M. Li, J. Peng, R.M. Friedlander, and L.H. Tsai Neurotoxicity induces cleavage of p35 to p25 by calpain Nature 405 2000 360 364
29. J.H. Lee, H.S. Kim, S.J. Lee, and K.T. Kim Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death J. Cell. Sci. 120 2007 2259 2271
30. J. Lew, R.J. Winkfein, H.K. Paudel, and J.H. Wang Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2 J. Biol. Chem. 267 1992 25922 25926
31. F. Liu, K. Iqbal, I. Grundke-Iqbal, and C.X. Gong Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta FEBS Lett. 530 2002 209 214
32. R. Liu, B. Tian, M. Gearing, S. Hunter, K. Ye, and Z. Mao Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion Proc. Natl. Acad. Sci. USA 105 2008 7570 7575
33. M. Malumbres, and M. Barbacid Mammalian cyclin-dependent kinases Trends Biochem. Sci. 30 2005 630 641
34. L. Meijer, A. Borgne, O. Mulner, J.P. Chong, J.J. Blow, N. Inagaki, M. Inagaki, J.G. Delcros, and J.P. Moulinoux Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur. J. Biochem. 243 1997 527 536
35. Y. Mettey, M. Gompel, V. Thomas, M. Garnier, M. Leost, I. Ceballos-Picot, M. Noble, J. Endicott, J.M. Vierfond, and L. Meijer Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects J. Med. Chem. 46 2003 222 236
36. M. Nikolic, H. Dudek, Y.T. Kwon, Y.F. Ramos, and L.H. Tsai The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation Genes Dev. 10 1996 816 825
37. C.A. O'Brian, R.M. Liskamp, D.H. Solomon, and I.B. Weinstein Inhibition of protein kinase C by tamoxifen Cancer Res. 45 1985 2462 2465
38. C.A. O'Brian, R.M. Liskamp, D.H. Solomon, and I.B. Weinstein Triphenylethylenes: a new class of protein kinase C inhibitors J. Natl. Cancer Inst. 76 1986 1243 1246
39. C.A. O'Brian, G.M. Housey, and I.B. Weinstein Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue Cancer Res. 48 1988 3626 3629
40. C.A. O'Brian, N.E. Ward, and B.W. Anderson Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme J. Natl. Cancer Inst. 80 1988 1628 1633
41. T. Ohshima, J.M. Ward, C.G. Huh, G. Longenecker, Veeranna, H.C. Pant, R.O. Brady, L.J. Martin, and A.B. Kulkarni Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death Proc. Natl. Acad. Sci. USA 93 1996 11173 11178
42. S. Okada, E. Yamada, T. Saito, K. Ohshima, K. Hashimoto, M. Yamada, Y. Uehara, T. Tsuchiya, H. Shimizu, and K. Tatei CDK5-dependent phosphorylation of the Rho family GTPase TC10(alpha) regulates insulin-stimulated GLUT4 translocation J. Biol. Chem. 283 2008 35455 35463
43. K. O'Neill, S. Chen, and R. Diaz Brinton Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease Exp. Neurol. 188 2004 268 278
44. G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, P. Dikkes, and L.H. Tsai Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration Nature 402 1999 615 622
45. D.W. Peterson, D.M. Ando, D.A. Taketa, H. Zhou, F.W. Dahlquist, and J. Lew No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro Proc. Natl. Acad. Sci. USA 107 2010 2884 2889
46. P. Polychronopoulos, P. Magiatis, A.L. Skaltsounis, V. Myrianthopoulos, E. Mikros, A. Tarricone, A. Musacchio, S.M. Roe, L. Pearl, and M. Leost Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases J. Med. Chem. 47 2004 935 946
47. J.N. Rich, and D.D. Bigner Development of novel targeted therapies in the treatment of malignant glioma Nat. Rev. Drug Discov. 3 2004 430 446
48. C.M. Sahlgren, A. Mikhailov, S. Vaittinen, H.M. Pallari, H. Kalimo, H.C. Pant, and J.E. Eriksson Cdk5 regulates the organization of Nestin and its association with p35 Mol. Cell. Biol. 23 2003 5090 5106
49. D.S. Smith, P.L. Greer, and L.H. Tsai Cdk5 on the brain Cell Growth Differ. 12 2001 277 283
50. J.R. Sundaram, C.P. Poore, N.H. Sulaimee, T. Pareek, A.B. Asad, R. Rajkumar, W.F. Cheong, M.R. Wenk, G.S. Dawe, and K.H. Chuang Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo J. Neurosci. 33 2013 334 343
51. C. Tarricone, R. Dhavan, J. Peng, L.B. Areces, L.H. Tsai, and A. Musacchio Structure and regulation of the CDK5-p25(nck5a) complex Mol. Cell 8 2001 657 669
52. W. Zhang, R.E. Law, D.R. Hinton, and W.T. Couldwell Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor Cancer Lett. 120 1997 31 38
53. B. Zhang, C. Corbel, F. Gueritte, C. Couturier, S. Bach, and V.B. Tan An in silico approach for the discovery of CDK5/p25 interaction inhibitors Biotechnol. J. 6 2011 871 881